Literature DB >> 3918553

Antinuclear antibodies in the relatives of patients with systemic sclerosis.

K Takehara, Y Moroi, Y Ishibashi.   

Abstract

Antinuclear antibodies were studied by indirect immunofluorescence and double immunodiffusion in 21 patients with systemic sclerosis and 35 of their relatives. When HEp-2 cells were used as the substrate, the frequency of antinuclear antibodies in the patients' sera was 100% and that in the relatives was 26%. When rat liver sections were used, the values were 86% and 17%, respectively. Anticentromere antibody was detected in the serum from the mother of one patient whose serum had anti-Scl-70 antibody. Antibody to n-RNP was positive in the sera from the brother and daughter of another patient whose serum was positive for anti-n-RNP and anti-Scl-70 antibodies. The high frequency of antinuclear antibodies in the sera from the relatives of systemic sclerosis patients suggests that immunological abnormalities play a part in the pathogenesis of this condition.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3918553     DOI: 10.1111/j.1365-2133.1985.tb02287.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  10 in total

1.  The effects of scleroderma sera on endothelial cell survival in vitro.

Authors:  T Etoh; A Igarashi; K Iozumi; Y Ishibashi; K Takehara
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

2.  Antikinetochore and antitopoisomerase I antibodies in systemic scleroderma: comparative study using immunoblotted recombinant antigens, immunofluorescence, and double immunodiffusion.

Authors:  M Jarzabek-Chorzelska; M Blaszczyk; Z Kolacinska-Strasz; T Chorzelski; S Jabłońska; G G Maul
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

3.  Antinuclear antibodies in the relatives and spouses of patients with systemic sclerosis.

Authors:  P J Maddison; R P Skinner; R S Pereira; C M Black; B M Ansell; M I Jayson; N R Rowell; K I Welsh
Journal:  Ann Rheum Dis       Date:  1986-10       Impact factor: 19.103

4.  Lymphocytotoxic autoantibodies in progressive systemic sclerosis.

Authors:  K Herrmann; J Schaller; U F Haustein; C Baldauf; S Kiessig
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

5.  Serum concentration of procollagen type I carboxyterminal propeptide in systemic sclerosis.

Authors:  K Kikuchi; H Ihn; S Sato; A Igarashi; Y Soma; Y Ishibashi; K Takehara
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

6.  Evaluation of multiplexed fluorescent microsphere immunoassay for detection of autoantibodies to nuclear antigens.

Authors:  Thomas B Martins; Rufus Burlingame; Carlos A von Mühlen; Troy D Jaskowski; Christine M Litwin; Harry R Hill
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

Review 7.  Clinical aspects of systemic sclerosis (scleroderma).

Authors:  R M Silver
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

8.  Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma.

Authors:  H Ihn; S Sato; M Fujimoto; K Kikuchi; K Takehara
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

9.  Clinical evaluation of scleroderma spectrum disorders using a points system.

Authors:  H Ihn; S Sato; T Tamaki; Y Soma; T Tsuchida; Y Ishibashi; K Takehara
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

Review 10.  The clinical relevance of autoantibodies in scleroderma.

Authors:  Khanh T Ho; John D Reveille
Journal:  Arthritis Res Ther       Date:  2003-02-12       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.